Naveglitazar

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameNaveglitazar
Drug Alias Namenaveglitazar那格列扎naveglitazarumLY-9818LY-818 +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPeroxisome proliferator-activated receptor γ agonistsPeroxisome proliferator-activated receptor α agonists
TargetsPeroxisome proliferator-activated receptor γPeroxisome proliferator-activated receptor α
Therapy Area/IndicationsDiabetes Mellitus, Type 2
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesLigand Pharmaceuticals IncEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesEli Lilly And Company
Active IndicationsN/A
Inactive IndicationsDiabetes Mellitus, Type 2

Other Information

ATC CodeN/A
Related LinksKEGG